|
FY2020
12 months to Dec 31, 2020
|
FY2019
12 months to Dec 31, 2019
|
FY2018
12 months to Dec 31, 2018
|
|
|---|---|---|---|
| Collaboration revenue | |||
| Operating expenses: | |||
| Research and development | |||
| General and administrative | |||
| Change in fair value of contingent consideration | |||
| Impairment of intangible asset | |||
| Total operating expenses | |||
| Loss from operations | |||
| Interest income | |||
| Other income, net | |||
| Total other income (expense), net | |||
| Loss before benefit from income taxes | |||
| Benefit from income taxes | |||
| Net loss | |||
| Accretion of redeemable convertible preferred stock to redemption value | |||
| Net loss attributable to common stockholders | |||
| Net loss per share—basic and diluted | |||
| Weighted average common shares outstanding—basic and diluted |
Loading...
